Roxane Fights Vanda Antipsychotic Dose Patent In Fed. Circ.

Law360, Washington (December 5, 2017, 9:59 PM EST) -- Roxane Laboratories told a Federal Circuit panel Tuesday that Vanda Pharmaceuticals' dosage method patent for its antipsychotic Fanapt is “quintessential conventional activity,” in its effort to overturn a Delaware court's finding its proposed generic version of the drug infringed the patent.

In the oral arguments, Roxane fought a district court finding that a post-invention 400-fold increase in the value of Fanapt indicated the nonobviousness of the patent. Roxane said using the little-used dosage-adjustment patent, which halves dosage for patients with a certain genetic feature, can’t block...
To view the full article, register now.



Case Information

Case Title

Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals

Case Number



Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

September 26, 2016

Law Firms


Government Agencies


Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.